Therapeutic programs in development
Building a diversified pipeline of regenerative therapies powered by scalable and reproducible exosome biology.
Lead Program
EVerGel
Localized exosome therapy for digestive tissue regeneration
EverGel is our lead therapeutic program targeting complex perianal fistula,
a significant unmet medical need in Crohn’s disease (inflammatory bowel disease).
a significant unmet medical need in Crohn’s disease (inflammatory bowel disease).
Indication: Complex perianal fistula
A complex perianal fistula is an abnormal tract connecting the rectum to the skin outside the body. Despite available treatment options, complex perianal fistulas remain a significant unmet medical need and a main complication of Crohn disease.
A significant burden for Crohn’s disease patients
We focus on Crohn’s disease, a chronic inflammatory bowel disease in
which 40% of patients will develop a perianal fistula during their life time.
which 40% of patients will develop a perianal fistula during their life time.
0
of Crohn patients fail
to permanently close their fistula
to permanently close their fistula
0
new
patient/year
patient/year
0
patients
world wide
world wide
First-in-human studies in Crohn’s disease-associate
complex perianal fistula are planned for early 2027.
EVerGel is designed for localized regenerative activity
EVerGel combines stem cell-derived exosomes with a thermoresponsive hydrogel designed for local administration. The hydrgel enables controlled exosome release, improves retention at the site of injury, and fills irregular defects, including complex and difficult-to-access fistula tracts.
Demonstrated regenerative activity
in preclinical models
We focus on Crohn’s disease, a chronic inflammatory bowel disease in
which 40% of patients will develop a perianal fistula during their life time.
which 40% of patients will develop a perianal fistula during their life time.
